Background: A regimen of lopinavir/ritonavir (LPV/r) and raltegravir (RAL) demonstrated non-inferior efficacy relative to a regimen of LPV/r with nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) in primary analysis at 48 weeks. In this analysis we aim to assess durability of effect over 96 weeks. Methodology: A total of 541 HIV-1 infected adults virologically failing first-line NNRTI+2N(t)RTI were randomised to receive RAL+LPV/r (RAL) or 2-3 N(t) RTI+LPV/r (N(t)RTI) in an open-label trial at 37 sites in Africa, Asia, Australia, Europe and Latin America, . Eligibility criteria included no previous exposure to protease inhibitors (PI) and integrase strand transfer inhibitors (InSTI) and no active hepatitis B infection. Genotypic antiretroviral resistance testing (GART) was permitted. Differences between the proportion of participants with HIV-1 RNA (pVL) <200 copies/mL and <50 copies/mL by intention to treat were compared using chi-square statistics with a non-inferiority margin of -12%. Differences in biochemical, haematological and metabolic changes were assessed using T-tests. Results: Participants were 55% male; 42% Asian; 36% African; and14% Hispanic. At randomisation mean (sd) age was 38.8 (8.8) years, mean (sd) duration of 1st-line ART, 4.1 (2.8) years, mean (sd) plasma HIV-1 RNA, 4.2 (0.9) log copies/mL, and mean (sd) CD4+T-cells, 211 (157) cells/mm^3. 3.7% patients withdrew or were lost to follow-up by week 96 (5.5% N(t)RTI vs. 1.9% RAL arm) and19 patients died (11 in N(t)RTI arm vs. 8 in the RAL arm). In both arms 83% of participants remained on the randomized regimen through 96 weeks. pVL was< 200 copies/mL at 96 weeks in 80.4% in the RAL arm and 76.0% in the N(t)RTI arm (difference: 4.4 [95% confidence interval -2.6, 11.3]) and met non-inferiority criteria. Mean increases in CD4+ cell count (cell/mm^3) were similar in both arms. There were no differences in number of participants experiencing an adverse event or a serious adverse event; the RAL arm was associated with a significantly higher mean change in haemoglobin, lymphocytes, total cholesterol, HDL-cholesterol and LDL-cholesterol (Table 1). Conclusions: At 96 weeks, an N(t)RTI-sparing second-line regimen of LPV/r+RAL continued to demonstrate similar efficacy, safety and tolerability compared to a regimen containing LPV/r+2-3N(t)RTIs. These results support the use of a combination PI and InSTI regimen as an option following failure of 1st line NNRTI+2N(t)RTIs.